Health care professional survey of the Liberant thrombectomy device
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
Medtronic Endovascular · NCT07335341
This project will collect first-in-human case data to see if the Liberant thrombectomy device safely and effectively removes fresh, soft clots from peripheral arteries and veins in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 22 Years and up |
| Sex | All |
| Sponsor | Medtronic Endovascular (industry) |
| Locations | 1 site (Naples, Florida) |
| Trial ID | NCT07335341 on ClinicalTrials.gov |
What this trial studies
The Liberant Clinical Assessment is a multicenter, prospective per-patient clinician recollection survey collecting first-in-human use data for the Medtronic Liberant thrombectomy system. Treating clinicians will document each routine device use and enter case details within 72 hours to capture periprocedural incidents and device performance. At least 50 individual use cases from at least 10 participating clinicians will be aggregated by a third-party vendor. There is no patient follow-up; data collection captures a single time point and is limited to uses consistent with the device labeling.
Who should consider this trial
Good fit: Ideal candidates are adults aged 22 or older undergoing routine peripheral arterial or venous thrombectomy for fresh, soft emboli or thrombi treated according to the device labeling.
Not a fit: Patients under 22, those with chronic, organized thrombus not suitable for aspiration, or cases outside the device labeling are unlikely to benefit from inclusion.
Why it matters
Potential benefit: If successful, this could support the safety and performance profile of the Liberant device and help expand treatment options for adults needing peripheral clot removal.
How similar studies have performed: This is a first-in-human assessment of the Liberant device, although other aspiration and mechanical thrombectomy systems for peripheral clots have prior clinical use and published favorable results.
Eligibility criteria
Show full inclusion / exclusion criteria
Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria: 1. Patient treated is age ≥ 22 years at the time of procedure 2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure
Where this trial is running
Naples, Florida
- Naples Comprehensive Health — Naples, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: John R Laird Jr, MD — Medtronic Endovascular
- Study coordinator: Manasa Gudipally
- Email: manasa.gudipally@medtronic.com
- Phone: 763-514-4000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Venous Embolism of Lower Extremities, Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease